Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Post-oral fat-induced satiation is mediated by endogenous CCK and GLP-1 in a fat self-administration mouse model

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association between habitual sleep duration/quality and appetite markers in individuals with obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Decreased spontaneous activity in AMPK α2 muscle specific kinase dead mice is not caused by changes in brain dopamine metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Virtual reality as therapy in pscyhiatry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of ketogenic diet and ketone monoester supplement on acute alcohol withdrawal symptoms in male mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Use of ketogenic diets in the treatment of central nervous system diseases: a systematic review

    Research output: Contribution to journalReviewpeer-review

  4. Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glucagon-like peptide 1 (GLP-1) analogues are used for the treatment of type 2 diabetes. The ability of the GLP-1 system to decrease food intake in rodents has been well described and parallels results from clinical trials. GLP-1 receptors are expressed in the brain, including within the ventral tegmental area (VTA) and the nucleus accumbens (NAc). Dopaminergic neurons in the VTA project to the NAc, and these neurons play a pivotal role in the rewarding effects of drugs of abuse. Based on the anatomical distribution of GLP-1 receptors in the brain and the well-established effects of GLP-1 on food reward, we decided to investigate the effect of the GLP-1 analogue exendin-4 on cocaine- and dopamine D1-receptor agonist-induced hyperlocomotion, on acute and chronic cocaine self-administration, on cocaine-induced striatal dopamine release in mice and on cocaine-induced c-fos activation. Here, we report that GLP-1 receptor stimulation reduces acute and chronic cocaine self-administration and attenuates cocaine-induced hyperlocomotion. In addition, we show that peripheral administration of exendin-4 reduces cocaine-induced elevation of striatal dopamine levels and striatal c-fos expression implicating central GLP-1 receptors in these responses. The present results demonstrate that the GLP-1 system modulates cocaine's effects on behavior and dopamine homeostasis, indicating that the GLP-1 receptor may be a novel target for the pharmacological treatment of drug addiction.

Original languageEnglish
JournalPhysiology & Behavior
Volume149
Pages (from-to)262-8
Number of pages7
ISSN0031-9384
DOIs
Publication statusPublished - 1 Oct 2015

ID: 45789361